GlassScriptPhysician profile
Jorge M Ortega
NPI 1508852674
$7,363.34
in general payments reported to CMS, 2019-2025
19 companies · $1,049 in 2025
The $1,049 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,004 · 2020: $394 · 2021: $401 · 2022: $911 · 2023: $1,025 · 2024: $1,580 · 2025: $1,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,654.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,823.65 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,008.58 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Sunovion Pharmaceuticals INC. | $613.02 | 2019-2020 | |
| Genzyme Corporation | $611.98 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $578.73 | 2019-2025 | Ofev, Spiriva, Stiolto Respimat |
| Inspire Medical Systems, INC. | $297.16 | 2024 | Inspire |
| Paratek Pharmaceuticals, INC. | $267.69 | 2023-2025 | Nuzyra |
| Verona Pharma, INC. | $205.35 | 2025 | Ohtuvayre |
| Insmed, INC. | $196.47 | 2020-2025 | Brinsupri, Arikayce |
| Genentech USA, INC. | $153.78 | 2019-2022 | |
| Mylan Specialty L.P. | $149.34 | 2019-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $105.36 | 2019-2024 | Opsumit, Uptravi |
| Amgen INC. | $76.84 | 2022-2024 | Tezspire |
| United Therapeutics Corporation | $74.73 | 2023 | Tyvaso |
| Philips North America LLC | $66.21 | 2022-2024 | (Ak6) Vest Therapy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $60.18 | 2025 | Yupelri |
| Lilly USA, LLC | $32.56 | 2025 | Zepbound |
| Vapotherm INC | $26.27 | 2022 | |
| Hikma Pharmaceuticals USA | $15.44 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Ortega listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.